A Special Purpose Acquisition Company
Targeting the Life Science Companies that Enable and Support Innovation
Advantage
Synergy: Eli Casdin’s Investment Platform, Keith Meister’s Capital Markets & Board Expertise
Since 2012, Eli Casdin and his investment team’s returns have flowed from their reputation, built over years, as investor-partners, working from the inside to drive and support new developments. Their tireless, on-the-ground research, close relationships with the brightest scientists and management teams and investments focus on the
long-term. Their industry connections now include hundreds of critical business builders, specialists, and innovators, which we believe will allow CM Life Sciences to push forward into new opportunities while also capturing value overlooked, or left behind.
Keith Meister has an extensive history of creating value and effecting change at companies, by creating buy-in from management teams, directors, and shareholders. Focused on identifying market dislocations and adept at spotting differentiated points of view, Mr. Meister and the Corvex Management team have built success based on deep industry understanding and a willingness to take the longer term view while capitalizing on market inefficiencies. Prior to founding Corvex Management, Mr. Meister was Chief Executive Officer / Principal Executive Officer of Icahn Enterprises, a NYSE listed diversified holding company, where he grew assets from $1.5 billion to $18 billion while generating greater than 20% annual returns for shareholders. Mr. Meister has served as a director of 15 public companies and helped those companies structure and execute over $80 billion in transactions including spin-offs, asset sales, mergers, acquisitions and various forms of capital market transactions.
CM Life Sciences was founded to take advantage of a dynamic life science sector buoyed by innovation yet fragmented, where many companies are under-resourced and under-scaled. Significant and under-appreciated opportunities for consolidation are ready for engagement by a team versed in the trends and themes, and who can bring together the strongest of the new companies and management teams to capitalize on near- and far-term opportunities. CM Life Sciences is ready, bringing together the unique industry experience, operational expertise, and investment savvy of Eli Casdin and Keith Meister.
Opportunity
Research
Diagnose
Develop
*Revenue estimate for 2020
Investment Opportunities
OPPORTUNITY: The innovation-productivity cycle in life sciences is creating enormous and varied opportunities across the development continuum and ecosystem.
Ecosystem
Services and tools supporting drug discovery, development and manufacturing. Identifying operationally focused companies with regulated products and services that have long and lucrative life cycles.
Life Science
Tools
High value tools and services for R&D across academia, government and industry. Tremendous opportunity to combine workflows and solutions to create powerful synergies and growth.
Synthetic
Biology
New markets exploiting technological advances in engineering of biological systems. From human health to industrial markets the syn-bio manufacturing platform is the future few appreciate.
Diagnostics
Molecular diagnostics industry now realized with limited public opportunities for exposure. Imbalance between channel and content capabilities creates synergy opportunities.
Board of Directors
Eli Casdin – CEO
INDUSTRY LEADER IN LIFE SCIENCE INVESTING
Eli Casdin, Chief Investment Officer and Founder, founded Casdin Capital in 2011, which manages $3.3B, targeting public and private growth equity in the life sciences ecosystem. For the last 17 years, Eli has analyzed and invested in disruptive technology and their application, by developing a deep understanding of the disruptive technologies and from cultivating relationships with industry leading experts and scientists since the beginning of this industry. Prior to founding Casdin Capital, Eli was a vice president at Alliance Bernstein “thematic” based investment group where he focused on the implications of new technologies for the life science and healthcare sectors. He published the black book, “The Dawn of Molecular Medicine” detailing the accelerating wave of innovations in life sciences, and the next wave.
Keith Meister – Chairman
SIGNIFICANT EXPERIENCE AS OWNER/OPERATOR AND PUBLIC COMPANY BOARD MEMBER
Founder and CIO of Corvex Management, which manages $2.5bn, targeting high quality businesses that can benefit from constructive shareholder engagement, while generating a 20% annual return for shareholders. Served as director of 15 public companies and helped structure and execute over $80bn in transactions. Previously Vice Chairman and CEO of Icahn Enterprises. During Keith’s tenure assets grew from $1.5 billion to $18 billion while generating substantial shareholder returns. Served as director of 15 public company boards. History of creating shareholder value through improved corporate governance, capital allocation and operations.
Kevin Conroy, J.D. – Board Member
Kevin Conroy is chairman and chief executive officer of Exact Sciences Corporation. Exact Sciences strives to change lives through earlier detection and smarter answers for cancer patients. During his 11-year tenure as CEO, Exact Sciences collaborated with Mayo Clinic to develop Cologuard, a noninvasive DNA based colorectal cancer screening test, and grew from 4 employees to more than 4,000. In 2019, Exact Sciences’ acquisition of Genomic Health, Inc., united two of the industry’s strongest brands, Cologuard and Oncotype DX, and established the company’s position as the global leader in advanced cancer diagnostics. Kevin received a B.S. degree in electrical engineering from Michigan State University, and a Juris Doctorate from the University of Michigan Law School.
Troy Cox – Board Member
Troy Cox will serve on our board of directors following completion of this offering. Mr. Cox has served as Director of SOPHiA GENETICS SA since July 2019 and as Chairman since February 2020; Director of LetsGetChecked Inc since October 2019 and as Vice Chairman since May 2020; and Director at Zymeworks Inc. (NYSE: ZYME) since June 2019. Mr. Cox also serves as Director for on-profits Massachusetts BioTechnology Council (MassBio) and Dream Foundation. Mr. Cox previously led Foundation Medicine, Inc. as President and Chief Executive Officer from February 2017 to February 2019 including its acquisition by Roche in July 2018. His qualifications to serve on our board of directors include his extensive experience in the life sciences industry as an executive, and in connection with evaluation and execution of business transaction and merger opportunities. Mr. Cox received an M.B.A. at the University of Missouri and B.B.A. in Finance from the University of Kentucky.
Jason Kelly, Ph.D – Board Member
Dr. Jason Kelly is the co-founder and CEO of Ginkgo Bioworks. Ginkgo is a synthetic biology company that programs cells for customers in the chemical, pharmaceutical, food, and energy industries. The company recently raised over $900M in venture capital to expand their automated genetic engineering foundries. They have a $100M joint venture with Bayer to develop microbes for self-fertilizing crops, a $160M partnership with Roche to develop antibiotics and with Motif for making animalfree protein ingredients. Ginkgo is valued at approximately $4.5B and has been listed for the past three years on CNBC’s Disruptor 50 List of fast-growing companies. Jason received B.S. degrees in Chemical Engineering and Biology, and a Ph.D in Biological Engineering all from MIT.
Stephen Quake, Ph.D – Board Member
Dr. Stephen Quake is the Lee Otterson Professor of Bioengineering and Professor of Applied Physics at Stanford University and is co- President of the Chan Zuckerberg Biohub, a non-profit medical research organization located in San Francisco. Quake’s research has explored the nexus of biology, physics and technology development. He is well known for his pioneering work in microfluidic technologies, genomics, and non-invasive liquid biopsies, including developing noninvasive prenatal testing as a replacement for amniocentesis. He is a scientific founder of several companies, including Fluidigm (NASDAQ: FLDM), CareDX (NASDAQ: CDNA), Verinata (now part of Illumina ILMN), and KariusDX. He is currently scientific founder and director of Bluestar Genomics, Molecular Stethoscope, Mirvie and Iggenix. Dr. Quake received a B.S. in Physics and M.S. in Mathematics from Stanford University in 1991 and a doctorate in Theoretical Physics from the University of Oxford as a Marshall Scholar in 1994.
Summary
Big Market
- Life Sciences is an enormous addressable market undergoing massive secular growth and ripe for consolidation.
- Broad universe of private companies with intrinsically valuable assets and defensible IP.
Strong Team
- Casdin’s network and deep sector expertise are matched with Meister’s track record of creating value at large, public companies.
- Top tier independent directors enhance industry connectivity and operational experience.
Unique Platform
- CMLS II leverages Casdin proprietary deal flow and reputation as leading investor in the public and private life sciences market.
- CMLS II leverages Casdin proprietary deal flow and reputation as leading investor in the public and private life sciences market.
Ideal Structure
- CMLS II provides needed capital and a unique buy-andbuild strategy for growing Life Science companies which find it hard to access public capital markets but need to scale.
- Public currency enables business owners to participate in upside as CMLS II platform grows and create a next generation life science platform.
News
Harnessing the Power of Proteomics
Global commercial and technological leader for bio-pharma and clinical protein discovery, measurement and interpretation.
CM Life Sciences II Merger Announcement
SomaLogic, Leading AI-Data Driven Proteomics Platform for Advanced Research and Clinical applications, to Combine with CM Life Sciences II, to Drive Growth and Expand Technology …
CM Life Sciences II Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $240 Million Initial Public Offering
CM Life Sciences II Inc. (the “Company”) announced today that it priced its initial public offering of 24,000,000 units at $10.00 per unit.
SEC Filings
Link to all items filed with the Securities and Exchange Commission